Showing 1 - 10 of 1,437
Background:Background: When guidelines for health economic evaluations prescribe that a societal perspective should be … national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include …
Persistent link: https://www.econbiz.de/10011005068
Persistent link: https://www.econbiz.de/10011005069
cancer have reported only modest gains in survival. These health gains are achieved at considerable cost, but economic … the bibliographic databases PubMed, EMBASE and Health Economic Evaluations (HEED) [via the Cochrane Library] for …
Persistent link: https://www.econbiz.de/10011005070
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071
Background:Background: National EQ-5D value sets are developed because preferences for health may vary in different … populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were … national value sets. Participants in the UK and US studies assessed the same subset of 42 EQ-5D health states using the time …
Persistent link: https://www.econbiz.de/10011005072
Background: Research has consistently demonstrated a relationship between depression and increased levels of health … economic impact of non-remission on health service use and costs over 12 months from the index episode in patients with … health service use and cost over the 12-month study period, by remission status, where remission is defined as patients not …
Persistent link: https://www.econbiz.de/10011005073
Background: Denosumab has recently been shown to be well tolerated, to increase bone mineral density (BMD) and to significantly reduce the risk of hip, vertebral and non-vertebral fractures in the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial. It is...
Persistent link: https://www.econbiz.de/10011005074
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
The design of decision-analytic models for cost-effectiveness analysis has been the subject of discussion. The current work addresses this issue by noting that, when time is to be explicitly modelled, we need to represent phenomena occurring in continuous time. Models evaluated in continuous...
Persistent link: https://www.econbiz.de/10011005076
Persistent link: https://www.econbiz.de/10011005077